Identification and Elimination of Antifungal Tolerance in <i>Candida auris</i>

Antimicrobial resistance is a global health crisis to which pathogenic fungi make a substantial contribution. The human fungal pathogen <i>C. auris</i> is of particular concern due to its rapid spread across the world and its evolution of multidrug resistance. Fluconazole failure in <...

Full description

Bibliographic Details
Main Authors: Samira Rasouli Koohi, Shamanth A. Shankarnarayan, Clare Maristela Galon, Daniel A. Charlebois
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/11/3/898
Description
Summary:Antimicrobial resistance is a global health crisis to which pathogenic fungi make a substantial contribution. The human fungal pathogen <i>C. auris</i> is of particular concern due to its rapid spread across the world and its evolution of multidrug resistance. Fluconazole failure in <i>C. auris</i> has been recently attributed to antifungal “tolerance”. Tolerance is a phenomenon whereby a slow-growing subpopulation of tolerant cells, which are genetically identical to susceptible cells, emerges during drug treatment. We use microbroth dilution and disk diffusion assays, together with image analysis, to investigate antifungal tolerance in <i>C. auris</i> to all three classes of antifungal drugs used to treat invasive candidiasis. We find that (1) <i>C. auris</i> is tolerant to several common fungistatic and fungicidal drugs, which in some cases can be detected after 24 h, as well as after 48 h, of antifungal drug exposure; (2) the tolerant phenotype reverts to the susceptible phenotype in <i>C. auris</i>; and (3) combining azole, polyene, and echinocandin antifungal drugs with the adjuvant chloroquine in some cases reduces or eliminates tolerance and resistance in patient-derived <i>C. auris</i> isolates. These results suggest that tolerance contributes to treatment failure in <i>C. auris</i> infections for a broad range of antifungal drugs, and that antifungal adjuvants may improve treatment outcomes for patients infected with antifungal-tolerant or antifungal-resistant fungal pathogens.
ISSN:2227-9059